Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TCR2 THERAPEUTICS INC.

(TCRR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about TCR2 THERAPEUTICS INC.
01/19Goldman Sachs Analyst Starts TCR2 Therapeutics at Neutral, Down From Buy, Sets $5 Price..
MT
01/13HC Wainwright Adjusts TCR2 Therapeutics Target Price to $19 From $25, Maintains Buy Rat..
MT
01/13TCR2 Therapeutics Inc. Announces Appointment of Rosemary Harrison as Chief Business and..
CI
01/13Tcr-2 therapeutics announces experienced biotech executive rosemary harrison as chief b..
AQ
01/12TCR2 Therapeutics Appoints Chief Business and Strategy Officer
MT
01/12TCR▓ Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Bu..
AQ
01/11Tcr-2 therapeutics announces 2022 strategic priorities and anticipated milestones
AQ
01/10Wedbush Lowers Price Target for TCR2 Therapeutics to $8 From $10, Maintains Neutral Rat..
MT
01/10Tcr-2 therapeutics to present at the j.p. morgan healthcare conference
AQ
01/10TCR▓ Therapeutics Announces 2022 Strategic Priorities and Anticipated Milestones
GL
01/10TCR▓ Therapeutics Announces 2022 Strategic Priorities and Anticipated Milestones
GL
01/07TCR▓ Therapeutics to Present at the J.P. Morgan Healthcare Conference
GL
01/07TCR▓ Therapeutics to Present at the J.P. Morgan Healthcare Conference
GL
01/06Tcr-2 therapeutics to present at the h.c. wainwright bioconnect conference
AQ
01/05Tcr-2 therapeutics and arbor biotechnologies establish collaboration to advance allogen..
AQ
01/05TCR▓ Therapeutics to Present at the H.C. Wainwright BioConnect Conference
AQ
01/04TCR2 Agrees Strategic Collaboration With Arbor Biotechnologies to Develop TRuC-T Cell T..
MT
01/04TCR▓ Therapeutics and Arbor Biotechnologies Establish Collaboration to Advance Allogene..
AQ
01/04TCR2 Therapeutics Inc. and Arbor Biotechnologies Establish Collaboration to Advance All..
CI
2021TCR2 THERAPEUTICS INC.(NASDAQGS : TCRR) dropped from S&P Biotechnology Select Industry Ind..
CI
2021TCR2 Therapeutics Inc. Announces Resignation of Mayur Somaiya, Effective December 10, 2..
CI
2021Tcr-2 therapeutics reports third quarter 2021 financial results and provides corporate ..
AQ
2021TCR2 THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
2021TCR2 Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate U..
PU
2021TCR▓ Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate U..
AQ
2021TCR2 Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
2021TCR2 Therapeutics Announces Expansion of U.S. Manufacturing Capacity - Form 8-K
PU
2021TCR2 THERAPEUTICS INC. : Costs Associated with Exit or Disposal Activities, Financial Stat..
AQ
2021TCR▓ Therapeutics Announces Expansion of U.S. Manufacturing Capacity
AQ
2021Tcr2 Therapeutics Inc. Announces Expansion of U.S. Manufacturing Capacity
CI
2021TCR2 Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers S..
PU
2021TCR2 THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Tcr-2 therapeutics announces clinical trial collaboration agreement with bristol myers ..
AQ
2021TCR2 THERAPEUTICS : Initiates Clinical Trial Partnership With Bristol Myers Squibb to Eval..
MT
2021BRISTOL MYERS SQUIBB : TCR▓ Therapeutics Announces Clinical Trial Collaboration Agreement ..
AQ
2021TCR2 THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2021NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
2021TCR2 THERAPEUTICS : Wedbush Trims Price Target for TCR2 Therapeutics to $10 From $11, Main..
MT
2021TCR2 THERAPEUTICS : SVB Leerink Downgrades TCR2 Therapeutics to Market Perform from Outper..
MT
2021TCR2 THERAPEUTICS : Tcr-2 therapeutics reviews pipeline and strategy at r&d day
AQ
2021TCR2 THERAPEUTICS : Press release issued by TCR2 Therapeutics Inc. on October 20, 2021 - F..
PU
2021TCR2 THERAPEUTICS INC. : Regulation FD Disclosure, Other Events, Financial Statements and ..
AQ
2021TCR2 THERAPEUTICS : TCR▓ Therapeutics Reviews Pipeline and Strategy at R&D Day
AQ
2021TCR2 Therapeutics Inc. Reviews Pipeline and Strategy At R&D Day
CI
2021TCR2 THERAPEUTICS : Tcr-2 therapeutics to host r&d day on october 20, 2021
AQ
2021TCR2 THERAPEUTICS : TCR▓ Therapeutics to Host R&D Day on October 20, 2021
AQ
2021TCR2 THERAPEUTICS : Tcr-2 therapeutics presents preclinical data on il-15 enhanced trucs a..
AQ
2021TCR2 THERAPEUTICS : TCR▓ Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at..
AQ
2021TCR▓ Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Spe..
CI
2021TCR2 THERAPEUTICS : HC Wainwright Adjusts TCR2 Therapeutics' Price Target to $25 from $37,..
MT
2021TCR2 THERAPEUTICS : Tcr-2 therapeutics announces positive interim results from ongoing pha..
AQ
2021TCR2 THERAPEUTICS : Truist Securities Adjusts Price Target on TCR2 Therapeutics to $29 Fro..
MT
2021TCR2 THERAPEUTICS : Must Arrange Additional Trials For Solid Tumors Treatment to Support E..
MT
2021TCR2 THERAPEUTICS : Tumble Following Interim Results From Trial of Gavo-cel to Treat Solid..
MT
2021TCR2 THERAPEUTICS : Wedbush Moves to the Sidelines and Downgrades TCR2 Therapeutics to Neu..
MT
2021NASDAQ 100 : Top Midday Decliners
MT
2021TCR2 THERAPEUTICS : Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gav..
PU
2021TCR2 THERAPEUTICS INC. : Regulation FD Disclosure, Other Events, Financial Statements and ..
AQ
2021TCR2 THERAPEUTICS : Reports Interim Result From Phase 1/2 Trial of Gavo-cel to Treat Solid..
MT
2021TCR▓ Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Ga..
GL
2021TCR▓ Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Ga..
CI
2021TCR2 THERAPEUTICS : to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel ..
AQ
2021TCR2 THERAPEUTICS : Tcr-2 therapeutics to present at the h.c. wainwright global investment..
AQ
2021TCR2 THERAPEUTICS : TCR▓ Therapeutics to Present at the H.C. Wainwright Global Investment ..
AQ
2021TCR2 THERAPEUTICS : Tcr-2 therapeutics receives fda orphan drug designation for gavo-cel f..
AQ
2021TCR2 THERAPEUTICS : Receives FDA Orphan Drug Designation for Gavo-Cel; Shares Rise Early
MT
2021TCR▓ Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment o..
GL
2021TCR▓ Therapeutics Receives FDA Orphan Drug Designation for Gavo-Cel for the Treatment o..
CI
2021TCR Therapeutics Gets FDA Orphan Designation for Gavo-cel in Bile-Duct Cancer
DJ
2021TCR2 THERAPEUTICS : Tcr-2 therapeutics announces renowned translational medicine leader pr..
AQ
2021TCR2 THERAPEUTICS : Announces Renowned Translational Medicine Leader Priti Hegde Joins Its..
PU
2021TCR2 THERAPEUTICS INC. : Change in Directors or Principal Officers, Financial Statements a..
AQ
2021TCR2 THERAPEUTICS : TCR▓ Therapeutics Announces Renowned Translational Medicine Leader Pri..
AQ
2021TCR2 Therapeutics Inc. Announces Board Changes
CI
2021TCR2 THERAPEUTICS : Tcr-2 therapeutics announces upcoming medical meetings update
AQ
1  2  3  4Next
Upcoming event on TCR2 THERAPEUTICS INC.